Europe
LGC Axolabs announces a significant investment at its site at Kulmbach, Germany, to expand the capacity of its specialist therapeutic oligonucleotide development solutions business and create a new GMP analytical capability.
Antibiotics have saved many lives by rescuing patients with bacterial or fungal infections, but these valuable drugs also have a dark side. As most medical drugs, also many antibiotics can have undesired effects on the body’s metabolism, causing more or less severe symptoms.
Certificate from AGES, the Austrian Agency for Health and Food Safety, endorses GMP conformity to Rentschler Fill Solutions’ new top-of-class facility.
Collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA
Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies
Almac Group is delighted to announce its global analytical services capabilities spanning UK, Europe and North America.
Investment will fund the global commercialization of Owlstone Medical’s Breath Biopsy® platform for early disease detection and precision medicine
Sareum Holdings plc announces its results for the year ended 30 June 2018 and provides an update of significant post-period events.
Up to half of people with Alzheimer’s disease (AD) use a psychotropic drug, and one in five uses two or more psychotropics concomitantly, according to a study conducted at the University of Eastern Finland.
Two antimalarial strategies have been published from Imperial College London in the past month: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.
PRESS RELEASES